On April 18, 2019, Harpoon Therapeutics, Inc. announced the dosing of their first patient with HPN536. HPN536 is a type of lab-created protein that causes T cells — special cells in the immune system — to target and attack mesothelioma and other cancer cells. Part 2 of the clinical trial will involve volunteers with mesothelioma.
The post What Patients Should Know About the New HPN536 Mesothelioma Clinical Trials appeared first on Mesothelioma Help Now.
from Mesothelioma Help Now https://ift.tt/2p18f5c
via IFTTT
What Patients Should Know About the New HPN536 Mesothelioma Clinical Trials
![What Patients Should Know About the New HPN536 Mesothelioma Clinical Trials]()
Reviewed by Unknown
on
October 01, 2019
Rating:
No comments: